Bill Gates invests in computational drug discovery firm

Related tags Chemistry

Nimbus Discovery has signed up Microsoft CEO Bill Gates and Richard Friesner, co-founder of chemical simulation software developer Schrodinger, as investors.

Massachusetts-based Nimbus uses computational chemistry to identify drug candidates for ‘difficult-to-treat’ diseases including cancers, inflammatory disorders and metabolic conditions.

Nimbus announced the news as part of an extension to its first financing round, explaining that it “follows a $10m investment by Bill Gates in Schrödinger to accelerate R&D efforts​.”

Chairman Bruce Booth explained that: “Their investment recognizes the unique opportunity Nimbus has to leverage Schrödinger’s 20-year technology investment with a virtually-integrated, globally distributed R&D approach​.”

Nimbus established an exclusive partnership with Schrodinger in 2010, under which it has exclusive rights to use of customized software packages and support services.

Related topics Preclinical Research Preclinical

Related news

Related products

show more

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us

Products

View more

Webinars